About
Linus Health is revolutionizing brain health by combining advanced AI with rigorously validated cognitive science to power the next generation of digital assessments. At its core is the Cognitive Care Engine (CCE), a flagship assessment that leverages the Boston Process Approach—a sensitive, process-based methodology that captures richer clinical insights in less time than traditional paper-based testing. A standout feature is its digitized Clock Drawing Test, which uses computer vision to analyze drawing process metrics far beyond what standard scoring captures. The platform serves a wide range of use cases: medical practices benefit from streamlined, fast cognitive assessments and clinical decision support; health systems can deploy Linus Health at scale to boost early detection, specialty triage, and patient outcomes; life sciences companies leverage validated digital tools to advance cognitive research and clinical trials; and payers can implement proactive cognitive health strategies to reduce long-term costs. Linus Health's approach is built on peer-reviewed science and continuously evolving evidence-based AI, enabling clinicians and researchers to detect subtle cognitive changes earlier than conventional methods. By bridging clinical care and research-grade analytics, Linus Health helps organizations move from reactive treatment to proactive cognitive care—ultimately improving outcomes for patients at risk of dementia and other brain health conditions.
Key Features
- Cognitive Care Engine (CCE): A flagship digital assessment that uses process-based metrics to detect early cognitive changes with greater sensitivity than traditional clinical tests.
- Boston Process Approach: A scientifically advanced methodology that captures how patients perform tasks—not just outcomes—enabling richer cognitive insights in less assessment time.
- AI-Powered Clock Drawing Test: A digitized version of the classic clock drawing cognitive test, analyzed using computer vision to extract nuanced process metrics invisible to manual scoring.
- Clinical Decision Support: Provides clinicians with actionable insights and risk indicators to guide care decisions, specialty referrals, and personalized treatment planning.
- Scalable Research & Trial Analytics: Offers validated digital cognitive assessments and population-level analytics to support clinical trial recruitment, monitoring, and cognitive research breakthroughs.
Use Cases
- Medical practices screening patients for early signs of dementia or Alzheimer's disease during routine visits using fast, validated digital assessments.
- Health systems deploying cognitive assessments at scale across primary care and specialty clinics to improve early detection rates and streamline specialty referrals.
- Life sciences companies integrating Linus Health's digital cognitive tools into clinical trials to measure cognitive outcomes with greater precision and scalability.
- Health insurance payers launching proactive cognitive health programs to identify at-risk members early and deploy care management resources cost-effectively.
- Academic researchers and neurologists using Linus Health's process-based analytics and peer-reviewed datasets to advance understanding of cognitive aging and neurodegeneration.
Pros
- Science-Validated Methodology: Built on peer-reviewed research and the Boston Process Approach, ensuring clinically credible and defensible assessments trusted by leading health systems.
- Earlier Detection Capability: Process-based digital metrics catch subtle cognitive decline earlier than conventional paper assessments, enabling timely intervention.
- Versatile Across Care Settings: Designed for medical practices, enterprise health systems, life sciences, and payers—making it adaptable across the full spectrum of cognitive care delivery.
- Reduces Administrative Burden: Streamlined digital workflows and automated scoring save clinician time while improving assessment consistency and throughput.
Cons
- Enterprise-Focused Pricing: Linus Health is designed for institutional buyers; there is no self-serve or consumer-facing option, making it inaccessible to individual practitioners or small clinics without a sales engagement.
- Narrow Domain Specialization: The platform is purpose-built exclusively for cognitive and brain health assessment, limiting applicability for organizations seeking broader clinical AI capabilities.
- Implementation Requires Onboarding: Deploying Linus Health at scale in a health system or research organization likely requires significant integration and workflow configuration effort.
Frequently Asked Questions
What is the CCE and how does it work?
The Cognitive Care Engine (CCE) is Linus Health's flagship digital assessment. It uses the Boston Process Approach to measure not just task outcomes but how a patient performs cognitive tasks, capturing process-based metrics that reveal early signs of cognitive decline with greater sensitivity than traditional tests.
Who is Linus Health designed for?
Linus Health serves medical practices, health systems, life sciences companies, and health insurance payers. It is purpose-built for clinical and research settings that need validated, scalable cognitive assessment tools.
What is the Boston Process Approach?
The Boston Process Approach is a cognitive assessment methodology that focuses on how a person completes a task rather than just the final answer. By analyzing error types and process patterns, it delivers richer diagnostic insights and greater sensitivity to early cognitive changes.
Can Linus Health be used in clinical trials?
Yes. Life sciences organizations use Linus Health's validated digital cognitive assessments and advanced analytics to support clinical trial design, participant screening, longitudinal monitoring, and population-level cognitive research.
How does Linus Health support early Alzheimer's detection?
Linus Health combines AI-driven digital assessments with evidence-based cognitive science to identify subtle changes in cognitive function before symptoms become clinically apparent. Its tools are designed to complement emerging biomarker-based diagnostics, such as FDA-cleared blood tests for Alzheimer's-related proteins.
